Browse our comprehensive library of diagnostic capabilities. We provide over 200 NABL accredited radiology scans and automated clinical pathology investigations.
First of all, Non-Invasive ctDNA Cancer Test is the breakthrough non-invasive genomic assay that analyzes circulating tumor DNA (ctDNA) shed into peripheral blood plasma. Essentially, ultra-deep Next-Generation Sequencing (>10,000X depth) detects somatic driver mutations, drug resistance variants, and gene fusions down to 0.1% variant allele frequency without surgical tumor biopsies. Consequently, medical oncologists select FDA-approved targeted therapies and monitor disease recurrence in real time.
Furthermore, book your Non-Invasive ctDNA Cancer Test at Henotic Diagnostics for authoritative precision oncology results. In addition, our accredited genomic laboratory operates 24/7 with specialized Streck cell-free DNA blood collection kits.
To begin with, Non-Invasive ctDNA Cancer Test is an advanced, non-invasive genomic diagnostic test that captures fragments of circulating tumor DNA (ctDNA) circulating freely in blood plasma. At the same time, experts at Henotic Diagnostics extract cell-free DNA from blood samples to profile active tumor mutations without requiring painful tissue biopsies.
Specifically, Non-Invasive ctDNA Cancer Test evaluates actionable somatic driver mutations (EGFR, KRAS, BRAF, ALK, ROS1, RET), copy number variations, and resistance variants down to 0.1% sensitivity. Consequently, bioinformatic algorithms analyze tumor-derived ctDNA shed from both primary tumors and distant metastases. Furthermore, serial liquid biopsies detect early disease relapse months before radiological detection. As a result, oncologists adjust targeted therapies proactively. In fact, to review liquid biopsy diagnostic guidelines, consult the NCI Liquid Biopsy Cancer Treatment.
In general, dying cancer cells release small fragments of mutated genomic DNA (ctDNA) into the bloodstream. Essentially, Non-Invasive ctDNA Cancer Test uses ultra-deep Next-Generation Sequencing (>10,000X coverage) to isolate and sequence these minute ctDNA fragments from blood plasma. Therefore, specialized bioinformatic error-suppression methods distinguish true tumor mutations from background noise. Additionally, to read about clinical liquid biopsy advances, examine the Nature Reviews Clinical Oncology journal.
Additionally, high-throughput NGS sequencers isolate and sequence plasma ctDNA down to 0.1% allele frequency
What Does Liquid Biopsy NGS Check?
Overall, clinical Non-Invasive ctDNA Cancer Test profiling evaluates key oncogenic categories:
Targetable Driver Mutations: First, screens EGFR (Exon 19 del, L858R), KRAS (G12C, G12D), BRAF V600E, PIK3CA, and HER2.
✓
Acquired Drug Resistance Variants: Second, detects emergent EGFR T790M, C797S, MET amplification, and ESR1 mutations during therapy.
✓
Targetable Plasma Gene Fusions: In addition, identifies ALK, ROS1, RET, and NTRK fusions in cell-free RNA/DNA. Review the ClinVar NCBI ctDNA variant database.
✓
Minimal Residual Disease (MRD) Tracking: Finally, measures post-surgical ctDNA clearance to detect early molecular relapse.
In addition, bioinformatic software maps ctDNA mutant allele frequencies and targeted drug response databases
When Is Liquid Biopsy NGS Recommended?
For example, medical oncologists order Non-Invasive ctDNA Cancer Test when surgical tissue biopsy is unsafe, unfeasible, or yields insufficient tissue (NSCLC, colorectal, breast, pancreatic cancer). In particular, testing is recommended upon disease progression during targeted therapy to identify resistance mechanisms without re-biopsy. Moreover, it is used for longitudinal tumor monitoring and post-operative MRD surveillance. In addition, to review NCCN precision oncology guidelines, examine the NCCN Precision Oncology Guidelines.
Ideally, oncologists choose Non-Invasive ctDNA Cancer Test because invasive tissue re-biopsies carry surgical risks, long scheduling delays, and sample bias from a single tumor location. In addition, blood ctDNA captures shed mutations from all metastatic lesions simultaneously. Indeed, to review global cancer diagnostic statistics, consult the WHO Cancer & Diagnostics Fact Sheet.
In addition, multi-cancer 500+ gene ctDNA costs ₹68,000 – ₹75,000
Specialized Streck cfDNA Blood Collection Kit
Finally, Streck blood tube kit delivery is complimentary.
Comparison: Liquid Biopsy NGS vs. Tissue Biopsy NGS
On one hand, Tissue Biopsy NGS remains the diagnostic benchmark when tissue is abundant, whereas Liquid Biopsy NGS offers rapid, non-invasive testing when tissue is unavailable or when monitoring therapy resistance over time. Consequently, both modalities complement modern precision oncology. In fact, review the PubMed Clinical Liquid Biopsy Review.
Feature
Liquid Biopsy NGS (ctDNA)
Tissue Biopsy NGS (FFPE)
Invasiveness & Safety
First, 100% non-invasive peripheral blood draw.
However, invasive surgical or core needle biopsy.
Turnaround Time
Second, fast report within 7 to 10 days.
In contrast, 14 to 21 days including block retrieval.
Tumor Heterogeneity Capture
In addition, captures multi-metastatic ctDNA shedding.
Meanwhile, limited to single biopsy site.
Repeat Sampling Frequency
Finally, easily repeated serially during therapy.
Likewise, difficult to repeat serially.
Frequently Asked Questions
What is Liquid Biopsy NGS?▼
First, Non-Invasive ctDNA Cancer Test is a simple blood test that extracts and sequences circulating tumor DNA (ctDNA) shed into blood plasma by cancer cells.
How does Liquid Biopsy compare to a traditional tissue biopsy?▼
In addition, Liquid Biopsy requires only a blood sample without invasive surgery, while overcoming tumor spatial heterogeneity by capturing ctDNA shed from multiple tumor sites.
What sample is required for Liquid Biopsy NGS?▼
Generally, 10-20 mL of peripheral blood drawn into specialized cell-free DNA preservation tubes (Streck tubes) is required.
Do I need to fast before Liquid Biopsy NGS?▼
Because ctDNA profiling evaluates cell-free tumor DNA, fasting is unnecessary.
Can Liquid Biopsy NGS detect drug resistance mutations?▼
Furthermore, Liquid Biopsy NGS excels at tracking emergent resistance mutations like EGFR T790M or C797S during ongoing targeted cancer therapy.
What is the cost of Liquid Biopsy NGS?▼
Overall, high-precision Liquid Biopsy NGS ranges from ₹45,000 to ₹75,000 depending on panel size and gene target breadth.
Quick Appointment Booking
Schedule your Liquid Biopsy NGS with accredited genomic experts.
MBBS, MD (Molecular Genetic Pathology) · 15+ Years Clinical Experience
Furthermore, your Liquid Biopsy NGS data is evaluated by accredited molecular geneticists and bioinformaticians. Consequently, comprehensive reports empower oncologists with non-invasive ctDNA targeted therapy insights.
Real feedback from patients who completed Liquid Biopsy NGS testing with us.
⭐⭐⭐⭐⭐
“Liquid Biopsy NGS detected the EGFR T790M resistance mutation in my blood when lung tissue biopsy was too risky. Furthermore, changing my medication cleared the disease!”
– Vikram S.
Verified Patient Review
⭐⭐⭐⭐⭐
“Complimentary Streck blood tube kit delivery and extremely fast 7-day turnaround. In addition, the oncologist praised the clinical report depth.”
– Rekha M.
Verified Patient Review
⭐⭐⭐⭐⭐
“State-of-the-art NABL accredited ctDNA platform. Henotic Diagnostics is our trusted referral laboratory for non-invasive liquid biopsy monitoring.”
If you require Liquid Biopsy NGS for non-invasive ctDNA mutation profiling or resistance monitoring, do not delay. Call to schedule your sample collection.
Henotic Diagnostics
Second floor, Millennium Empire, Business Park, Plot No 47, D Mart Rd, Sector 15, Kharghar, Navi Mumbai, Panvel, Maharashtra 410210
You can book your Liquid Biopsy Ngs appointment at our Navi Mumbai center through multiple convenient channels: call us directly at 088793 27184, send a WhatsApp message for instant booking, or use the online booking form on our website. Walk-in appointments are also welcome based on slot availability. We recommend advance booking to ensure zero wait times.
Yes, Henotic Diagnostics Navi Mumbai is empanelled with all major insurance companies and TPAs (Third Party Administrators) including Star Health, ICICI Lombard, New India Assurance, HDFC Ergo, Max Bupa, Bajaj Allianz, and many more. We offer cashless processing for Liquid Biopsy Ngs where applicable. Please carry your insurance card and a valid ID for seamless processing.
At Henotic Diagnostics Navi Mumbai, most Liquid Biopsy Ngs reports are delivered within 2-6 hours for routine tests. Critical and urgent reports are expedited on a priority basis. All reports are delivered digitally via WhatsApp, email, and our secure online patient portal. Hard copies are also available at the center upon request. You will receive an SMS/WhatsApp notification the moment your report is ready.
Henotic Diagnostics Navi Mumbai operates 24 hours a day, 7 days a week, including Sundays and public holidays. This means you can schedule your Liquid Biopsy Ngs at a time that is most convenient for you — early morning, late evening, or even overnight for emergency requirements. Our radiology and pathology departments maintain round-the-clock availability.
Yes, Henotic Diagnostics Navi Mumbai is fully accredited by NABL (National Accreditation Board for Testing and Calibration Laboratories) and ISO 9001:2015 certified. Our radiology equipment also complies with AERB (Atomic Energy Regulatory Board) safety standards. These accreditations ensure that every Liquid Biopsy Ngs performed at our facility meets the highest national and international quality benchmarks for accuracy, safety, and reliability.
